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Serious bacterial infections in patients with
rheumatoid arthritis under anti-TNF-a therapy
S. Kroesen, A. F. Widmer1, A. Tyndall and P. Hasler
Objective. With rising numbers of anti-tumour necrosis factor a (TNF-a)
treatments for rheumatoid arthritis (RA), Crohn’s disease and other conditions,
physicians unaware of potential pitfalls are increasingly likely to encounter
associated severe infections. Our purpose was to assess the incidence and nature of
severe infections in our RA patients under anti-TNF-a therapy.
Methods. We reviewed patient charts and records of the Infectious Disease Unit
for serious infections in patients with RA in the 2 yr preceding anti-TNF-a therapy
and during therapy.
Results. Serious infections affected 18.3% of patients treated with infliximab or
etanercept. The incidence was 0.181 per anti-TNF-a treatment year vs 0.008 in the
2 yr preceding anti-TNF-a therapy. In several cases, only a few signs or symptoms
indicated the severity of developing infections, including sepsis.
Conclusions. A high level of suspicion of infection is necessary in patients under
anti-TNF-a therapy. We suggest additional strategies for the prevention, rapid
identification and pre-emptive therapy of such infections.
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The efficacy of the anti-tumour necrosis factor a (TNF-
a) agents infliximab and etanercept in the treatment of
rheumatoid arthritis (RA) has been demonstrated in
large-scale trials w1–4x. Their results indicate a superior
effect of these agents compared with conventional
disease-modifying anti-rheumatic drugs (DMARDs).
Among the undesired effects of anti-TNF-a agents,
infections have been a primary concern. Under study
conditions, 53% of patients in the group treated with
3 mgukg infliximab together with methotrexate had an
infection compared with 40% in the placebo group w1x.
For any given infection, the difference between the
groups was statistically significant. However, the inci-
dence of serious infections, defined as life-threatening or
requiring hospitalization, was not statistically different
over the dose ranges studied (6% for placebo vs 1% for
3 mgukg every 8 weeks to 6% for 10 mg every 4 weeks).
With etanercept, infections occurred in 51% of the
patients in the active treatment group compared with
63% in the placebo group w3x. On the basis of these data,
it was assumed that the incidence and severity of
infections were not markedly increased under treatment
with these agents when compared with other data on
infections in RA w5–7x.
Recently, anti-TNF-a therapy has been associated
with the reactivation of tuberculosis, again raising
concerns that infections may pose a significant threat
w8x. In addition to the existing warnings of potential
infections under etanercept and infliximab contained in
the package insert, in the case of the latter the FDA
(Food and Drug Administration, USA) requested
the addition of a ‘black box’ with recommendations
concerning tuberculosis. So far, postmarketing surveys
have not revealed significant problems with serious
infections under anti-TNF-a therapy. However, because
the nature and course of infectious disease may be
altered by anti-TNF-a therapy, it is of critical impor-
tance to consider this aspect in the care of patients.
We evaluated a series of serious infections from our
institution which highlight the potential pitfalls
and difficulties with infections under infliximab and
etanercept.
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Methods
From the onset of compassionate use and after approval for
clinical use in RA, all RA patients receiving the anti-TNF-a
agents etanercept and infliximab at our institution gave written
consent to be followed prospectively in a central national data
registry approved by the nationwide ethics committee of the
Swiss Academy for Medical Sciences w9x. In addition to the data
entered into the registry, other clinical information, including
all undesired effects after the beginning of anti-TNF-a therapy,
were recorded in the patient charts. The charts of all patients
were reviewed for any serious infection in the 2 yr preceding
anti-TNF-a therapy. A cross-check with the computerized
records of consultations by the Infectious Disease Unit and all
microbiology records at the University Hospital Basel was
performed on all patients with RA to identify any severe
infections that may have been missed in the patient charts.
Patients on anti-TNF-a therapy were managed by designated
physicians under close supervision by experienced board-
certified rheumatologists. We report all events classified as a
serious infection, defined as requiring hospitalization anduor
intravenous antibiotic therapy, which occurred from the
beginning of the anti-TNF-a programme in December 1999
up to May 2002 in patients followed at our out-patient unit.
The incidence of infections meeting these criteria was compared
with that during the last 24 months of conventional therapy in
the same patients before the beginning of anti-TNF-a therapy.
Infliximab was given on an out-patient basis as an
intravenous infusion at 3 mg of infliximabukg body weight
over 2 h, following the manufacturer’s instructions. Infusions
were given at time 0, 2 weeks and 6 weeks, and every 8 weeks
thereafter, except when indicated otherwise. In all cases,
infliximab was combined with methotrexate, which was given
at a dose between 7.5 and 20 mg once weekly. Etanercept was
given as twice-weekly subcutaneous injections of 25 mg except
when indicated otherwise. Initial injections were performed by
specialized nurses of the out-patient unit, and afterwards by the
patients themselves once they achieved adequate proficiency.
Results
A total of 60 patients were treated at our out-patient unit
during the period after October 1999. Thirty-six treat-
ment courses were started with etanercept and 28 with
infliximab, of which 34 and 18 respectively are ongoing.
Five patients switched from infliximab to etanercept, and
one from etanercept to infliximab. The median age was
52.98 yr (range 21.3–85.4 yr), 13 were males and 47 were
females. The median duration of RA was 12.4 yr (range
1.7–39.4 yr) and the median number of DMARDs was 3
(range 1–8). The median number of treatment months
per patient was 19.6 (range 4.0–33.14) for infliximab and
20.69 (range 2.14–32.1) for etanercept. The principal
features of the 11 patients with a serious infection are
summarized in Table 1. In the following, brief comments
are provided.
Patient 1 presented with pneumonia due to
Streptococcus pneumoniae and Pneumocystis carinii,
and patient 10 with pneumonia due to Staphylococcus
aureus. In both cases onset was abrupt, with chest pain
and dyspnoea. This was preceded by a slight cough
without discomfort or general symptoms. Patient 1 had
an isolated elevation of C-reactive protein (CRP) 4 days
before the onset and patient 10 had normal clinical,
laboratory and chest radiographic examinations only
2 days before the acute symptoms began. P. carinii was
detected in bronchial washings. Patient 10 had extensive
necrotizing abscesses of both lungs. Patient 2 had
bilateral Legionella pneumophila pneumonia and fever
but felt no distress.
Patient 3 was admitted because of nausea, loss of
appetite and failure to provide a urine sample in the
morning. Leucocytes were 18.03109ul and CRP was
249 mgul (normally<5.0 mgul). After admission, intense
abdominal pain and deterioration of her general condi-
tion evolved rapidly in the late afternoon. A CT scan
excluded diverticulitis, but catheter urine and all blood
cultures were positive for Escherichia coli. Patient 4
had normal clinical and laboratory examinations 2 days
before the acute onset of a foot abscess, probably
originating from a plantar bunion, with chills and fever.
Surgical drainage fluid and all blood cultures grew
S. aureus. In patient 6, a meniscal tear with prominent
effusion of the right knee was present. Joint fluid showed
scant growth of coagulase-negative staphylococci after
several days. A second and third joint aspirate showed
increasingly rapid growth and an increasing number
of leucocytes. Upon differentiation, Staphylococcus
lugdunensis was identified, a coagulase-negative species
with pathogenic potential similar to S. aureus in the
bloodstream w10x. Despite i.v. flucloxacillin, her condi-
tion worsened until an open, extensive synovectomy
was performed, whereupon recovery began w11x. Patients
7 and 11 developed severe diverticulitis with systemic
manifestations within hours; i.v. antibiotics were
initiated without delay and blood cultures remained
negative. Patient 8 had an unexpectedly rapid systemic
extension of a bladder infection.
These cases illustrate the variety of clinical presenta-
tions of serious infections associated with anti-TNF
therapy, the propensity to behave relatively innocuously
for an extended time, and their life-threatening nature.
There was no apparent predilection for a specific bacter-
ial agent. No tuberculosis or serious viral infections were
recorded. With the exception that the shortest interval
between initiation and infection was 22 weeks, we found
no relationship with the duration of inflixi-
mab or etanercept therapy. Also, there was no clustering
of infections at any point in the interval between
infliximab infusions. Temperature, erythrocyte sedimen-
tation rate and leucocyte counts were not consistently
altered, whereas CRP was uniformly elevated, in several
cases before the infection became evident locally or
systemically.
In seven of the 11 cases, it was possible to attribute
the clinically apparent infection to specific organisms,
exceptions being two patients with pneumonia and
two patients with diverticulitis. A broad variety of
agents and the possibility of multiple infections must be
considered in the diagnostic work-up. Coagulase-
negative staphylococci from patients under anti-TNF-a
therapy should be interpreted similarly to those in
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TABLE 1. Clinical features of patients with complications under anti-TNF-a therapy
Patient
Age (yr),
sex Diagnosis; DMARDs
Date of
diagnosis Comorbidity IFXuETC Concomitant therapy Infection Microorganism
1 30, F RA, RF2; MTX,
CYS, AU, LEF
2u1999 Bronchial asthma IFX 3 mgukg MTX 15 mguw,
PRD 30 mgud
Pneumonia, secondary
bloodstream infection
S. pneumoniae,
P. carinii
2 49, M RA, RF2; MTX,
CYP, CYS
1991 Psoriasis IFX 3 mgukg MTX 15 mguw Pneumonia L. pneumophila
(antigen only)
3 73, F Erosive RA, RF+;
HCL, MTX p.o.,
SAL, CYS, AU
3u1996 None ETC 1325mguw MTX 15 mguw,
PRD 10 mgud
Urosepsis, secondary
bloodstream infection
E. coli
4 66, F Erosive RA, RF+;
AU, SAL, MTX
1987 None IFX 3 mgukg MTX 10 mguw,
PRD 7.5 mgud
Foot abscess, secondary
bloodstream infection
S. aureus
5 42, F Rapidly progressive,
erosive RA, RF+;
MTX, SAL, HCL
1992 None IFX 3 mgukg MTX 10 mguw Pneumonia n.d.
6 72, F RA, RF2; HCL, SAL,
AU, PEN, CYS, CYP
1988 Heart failure ETC 2325 mguw None Septic knee arthritis,
secondary bloodstream
infection
S. lugdunensis
7 57, F RA, RF2; MTX, SAL, CYS 1995 None IFX 3 mgukg MTX 20 mguw,
PRD 10 mgud
Diverticulitis n.d.
8 38, F RA, RF+; PEN, MTX,
AZA, CYP, SAL, HCL
7u1993 Diffuse systemic
sclerosis
ETC 2325 mguw CYS 100 mgud
PRD 5 mgud
Pyelonephritis Proteus mirabilis
9 52, F RA; PEN, HCL, SAL, MTX 1976 Hypertension,
osteoporosis
ETC 2325 mguw PRD 5 mgud,
diclofenac 2350 mg
Pneumonia n.d.
10 61, F RA, RF+; MTX, SAL,
HCL, CYS
1966 Hypertension IFX 3 mgukg HCL 1 3 200mgud,
MTX 12.5 mguw,
PRD 10 mgud
Pneumonia S. aureus
11 66, F Erosive RA, RF+; MTX 8u1999 CHD, hypertension
Graves disease,
osteoporosis
ETC 2325 mguw PRD 5 mgud Diverticulitis n.d.
Infliximab and etanercept were administered as described under Methods.
AU, gold; CHD, coronary heart disease; CYP, cyclophosphamide; CYS, cyclosporin; d, day; ETC, etanercept; HCL, hydroxychloroquine; IFX, infliximab; LEF, leflunomide; MTX,
methotrexate; n.d., not determined; p.o., orally; PEN, D-penicillamine; PRD, prednisone; RF, rheumatoid factor; SAL, salazopyrin (sulphasalazine); w, week.
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patients with severe immunosuppression, and the species
should be identified.
The total number of months of treatment with
etanercept and infliximab, the number of months of
treatment with DMARDs before starting anti-TNF-a
therapy and the number and incidence of serious infec-
tions are shown in Table 2. There was a clear difference
in the incidence of serious infections before compared
with after anti-TNF-a therapy. Of all patients under
anti-TNF-a therapy, 18.3% had a serious infection.
Discussion
From the onset of clinical trials, a central concern of
cytokine blockade has been a potential increase in
susceptibility to infections. This was due to the central
role of cytokines, especially TNF-a and interleukin 1, in
mounting the inflammatory response. TNF-a in soluble
form increases the expression of adhesion molecules on
endothelial cells and activates neutrophils and macro-
phages. Surface-bound TNF-a is likely to be involved in
cell-to-cell interactions, possibly potentiating the activa-
tion of specific and non-specific immune effective cells.
Finally, it may also play a role in winding down
inflammation once surface-bound TNF-a receptors are
expressed. In spite of these considerations, no significant
increase in serious infections has been reported in studies
performed to evaluate the efficacy of anti-TNF-a agents
w12x. However, it is noteworthy that there may be a dose-
dependent increase in serious infections under anti-
TNF-a therapy w2x. Postmarketing surveys have not
shown a clear increase in the rate of serious infections,
apart from the reactivation of tuberculosis, though this
is infrequent w8x.
Both in relation to the number of treatments started
and of patient-years of treatment, the rates of serious
infections in our patients are approximately twice as high
as those reported in the efficacy studies w1–4x or
registered in postmarketing surveys. The difference in
incidence under anti-TNF-a agents cannot be explained
by different definitions of serious infections, because all
of our cases required hospitalization. In postmarketing
surveys, under-reporting, or a lack of reporting, may be
a significant factor. Given the highly effective reduction
in disease activity achieved by these agents, which also
occurred in our patient population, some adverse
outcomes may be acceptable. However, patient and
physician awareness must be tuned to recognize that the
course of infections may be fulminant and that every
effort must be made to clarify even slight alterations in
well-being. This is necessary because clinical and
laboratory signs may be blunted by TNF-a blockade
and by concomitant immunosuppressive medication. In
this respect, certain common features in our case series
indicate how to identify infections early. First and most
prominent is a rise in the CRP level, in which case an
infection must be ruled out immediately, even if this
involves extensive diagnostic procedures. Secondly,
positive blood cultures or synovial fluid cultures with
pathogens of low pathogenicity (e.g. coagulase-negative
staphylococci) must be taken seriously even though the
patient’s well-being is not or only slightly affected and
laboratory results are normal. Thirdly, once symptoms
become clinically overt, severe sepsis must be anticipated
and rapid deterioration averted.
Patients with RA, especially RA of long duration,
have a record of fatigue and recurrent episodes of reduced
well-being. They are used to managing these conditions
without seeking medical attention. Likewise, physicians
may be desensitized to potential warning signs. Con-
sidering the total number of treatments currently applied
and the potential for a widening of indications for the
use of anti-TNF-a agents, we strongly recommend that
institutions using these therapies provide safeguards 24 h
a day 7 days a week. Patient education is essential and
may benefit from a structured programme. Finally, the
question of immunization before the initiation of anti-
TNF-a therapy must be considered. At present there are
no data from controlled trials allowing specific recom-
mendations. However, a well-informed patient, a physi-
cian highly suspicious of infectious complications, and
rapid access to health-care will make it possible to take
advantage of this new treatment option while minimizing
potentially life-threatening complications.
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